Search Results - "Cid-Ruzafa, Javier"

This result is not displayed to guests.
Login for full access.

Linaclotide utilization and potential for off-label use and misuse in three European countries.

Authors: Cid-Ruzafa, Javier Lacy, Brian E. Schultze, Anna et al.

Source: Therapeutic Advances in Gastroenterology. 6/11/2022, Vol. 15, p1-14. 14p.

Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.

Authors: Cid Ruzafa, Javier Merinopoulou, Evie Baggaley, Rebecca F. et al.

Source: Pharmacoepidemiology & Drug Safety. Aug2016, Vol. 25 Issue 8, p871-879. 9p.

Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study.

Authors: Charbonnel, Bernard H. Chen, Hungta Cid‐Ruzafa, Javier et al.

Source: Diabetes, Obesity & Metabolism. Jan2023, Vol. 25 Issue 1, p46-55. 10p.

Evolution of economic burden of heart failure by ejection fraction in newly diagnosed patients in Spain.

Authors: Escobar, Carlos Palacios, Beatriz Gonzalez, Victoria et al.

Source: BMC Health Services Research. 12/1/2023, Vol. 23 Issue 1, p1-14. 14p.

Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction.

Authors: Escobar, Carlos Palacios, Beatriz Gonzalez, Victoria et al.

Source: Journal of Clinical Medicine. Mar2023, Vol. 12 Issue 6, p2410. 15p.

Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain.

Authors: Escobar, Carlos Palacios, Beatriz Varela, Luis et al.

Source: BMC Health Services Research. 10/8/2022, Vol. 22 Issue 1, p1-16. 16p. 5 Charts.

Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain.

Authors: Escobar, Carlos Palacios, Beatriz Varela, Luis et al.

Source: Journal of Clinical Medicine. Sep2022, Vol. 11 Issue 17, p5199. 18p.

Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme.

Authors: Khunti, Kamlesh Chen, Hungta Cid‐Ruzafa, Javier et al.

Source: Diabetes, Obesity & Metabolism. Jan2020, Vol. 22 Issue 1, p66-78. 13p.

Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model.

Authors: Starczewska Amelio, Justyna M Cid Ruzafa, Javier Desai, Kamal et al.

Source: BMC Cancer. 2014, Vol. 14 Issue 1, p364-364. 1p.

An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure.

Authors: Nikolaou, Andreas Hogea, Cosmina Samyshkin, Yevgeniy et al.

Source: Value in Health. Dec2022, Vol. 25 Issue 12, p1977-1985. 9p.

Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study.

Authors: Nicolucci, Antonio Chen, Hungta Cid-Ruzafa, Javier et al.

Source: Diabetes Research & Clinical Practice. Oct2021, Vol. 180, pN.PAG-N.PAG. 1p.

Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.

Authors: Patel, Krishna K. Gomes, Marilia B. Charbonnel, Bernard et al.

Source: Diabetes, Obesity & Metabolism. Jan2021, Vol. 23 Issue 1, p39-48. 10p.

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme.

Authors: Nicolucci, Antonio Charbonnel, Bernard Gomes, Marília B. et al.

Source: Diabetes, Obesity & Metabolism. Nov2019, Vol. 21 Issue 11, p2474-2485. 12p.

1628-P: Changes in HbA1c and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study.

Authors: CHARBONNEL, BERNARD CHEN, HUNGTA CID-RUZAFA, JAVIER et al.

Source: Diabetes. 2019 Supplement, Vol. 68, pN.PAG-N.PAG. 1p.

420-P: Micro- and Macrovascular Events in Patients with T2D—Results from the Global DISCOVER Study.

Authors: ARNOLD, SUZANNE V. CHEN, HUNGTA CID-RUZAFA, JAVIER et al.

Source: Diabetes. 2019 Supplement, Vol. 68, pN.PAG-N.PAG. 1p.

207-LB: Type 2 Diabetes and Heart Failure: Insights from the DISCOVER Study.

Authors: ARNOLD, SUZANNE V. CHEN, HUNGTA CID-RUZAFA, JAVIER et al.

Source: Diabetes. 2019 Supplement, Vol. 68, pN.PAG-N.PAG. 1p.

Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.

Authors: Gomes, Marilia B. Rathmann, Wolfgang Charbonnel, Bernard et al.

Source: Diabetes Research & Clinical Practice. May2019, Vol. 151, p20-32. 13p.

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.

Authors: Khunti, Kamlesh Godec, Thomas R. Medina, Jesús et al.

Source: Diabetes, Obesity & Metabolism. Feb2018, Vol. 20 Issue 2, p389-399. 11p.

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).

Authors: Kosiborod, Mikhail Gomes, Marilia B. Nicolucci, Antonio et al.

Source: Cardiovascular Diabetology. 11/28/2018, Vol. 17 Issue 1, pN.PAG-N.PAG. 1p. 3 Charts, 1 Map.